Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present.[…]
Full Archive
Tri-Modality Therapy Triples Survival Compared to Chemotherapy and Surgery Alone
A very aggressive mesothelioma treatment is proving to be more beneficial compared to just chemotherapy and surgery alone. The more aggressive therapy utilizes multiple techniques creating a more successful treatment in certain patients. Mesothelioma treatment needs to be aggressive because it is a tough to treat and aggressive cancer. People[…]
Pleurectomy/Decortication Surgery Can Improve Quality of Life, Even in Patients with Declining Lung Function
Researchers at the Hyogo College of Medicine have found that pleurectomy/decortication surgery can improve quality of life in mesothelioma patients, even if they have declining lung function. The researchers looked at 45 patients who received pleurectomy/decortication surgery between the years 2014 and 2018. After the patients received surgery, lung function[…]
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Primary Outcome Measures Number of patients with adverse events and serious adverse events [ Time Frame: 3 years ] Safety and tolerability of IAG933 Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only) [ Time Frame: 1 year ] Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933 Number of patients[…]
The Two Major Mesothelioma Surgeries Have Similar Death Rates
Japanese researchers have found that the main two types of surgery for mesothelioma have similar risks of death. The surgeries either remove the diseased lung lining and one of the lungs or just the lining. Doctors do not agree what surgery is best for mesothelioma patients, but both surgeries have[…]
A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will[…]
An Inhaled Vaccine Could Potentially Help Mesothelioma Patients in the Future
An inhaled vaccine could be used for mesothelioma treatment soon. Research done at MIT is showing that the inhaled vaccine can trigger an immune response for certain infections and possibly lung-based cancers. This is great news for people with mesothelioma. Lung infections typically start on mucosal membranes, so researchers created[…]
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma (SCITH-MESO)
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
A Phase III Clinical Trial is Looking at the Combination of Durvalumab and Chemotherapy to Treat Mesothelioma
A new clinical trial involving durvalumab should be closely monitored by the Food and Drug Administration. The phase III clinical trial is being performed in Baltimore, Cleveland, and Ann Arbor as well as places in New Zealand and Australia. The randomized trial is known as DREAM3R. It wants to figure[…]
